EC approves first-line ovarian cancer treatment
European Pharmaceutical Review
NOVEMBER 22, 2023
The safety profile for rucaparib observed in the clinical trial was consistent with current US and European labels for rucaparib. Since most patients have an initial response to the treatment, 80 percent will experience recurrence and require subsequent therapies, according to a 2012 paper published in Annals of Oncology.
Let's personalize your content